Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
National and Subnational Burden of Leukemia and Its Risk Factors, 1990-2019: Results From the Global Burden of Disease Study 2019 Publisher Pubmed



Poopak A1 ; Moghaddam SS1 ; Esfahani Z1, 2 ; Keykhaei M1, 3 ; Rezaei N1, 4 ; Rezaei N1, 4 ; Rashidi MM1 ; Ahmadi N1 ; Abbasikangevari M1 ; Malekpour MR1 ; Ghamari SH1 ; Djalalinia S5 ; Tavangar SM6 ; Larijani B4 Show All Authors
Authors
  1. Poopak A1
  2. Moghaddam SS1
  3. Esfahani Z1, 2
  4. Keykhaei M1, 3
  5. Rezaei N1, 4
  6. Rezaei N1, 4
  7. Rashidi MM1
  8. Ahmadi N1
  9. Abbasikangevari M1
  10. Malekpour MR1
  11. Ghamari SH1
  12. Djalalinia S5
  13. Tavangar SM6
  14. Larijani B4
  15. Kompani F7
Show Affiliations
Authors Affiliations
  1. 1. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Biostatistics, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
  3. 3. Feinberg Cardiovascular and Renal Research Institute, Northwestern University, School of Medicine, Chicago, IL, United States
  4. 4. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Deputy of Research and Technology, Ministry of Health and Medical Education, Tehran, Iran
  6. 6. Department of Pathology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Division of Hematology and Oncology, Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran

Source: PLoS ONE Published:2023


Abstract

Background Hematologic malignancies have a great essential role in cancer global burden. Leukemia which two major subtypes based on the onset, is one of the common subtypes of this malignancy. Method For the GBD 2019 study, cancer registry data and vital registration system were used to estimate leukemia mortality. The Meta-Regression-Bayesian Regularized Trimmed (MR-BRT), Cause of Death Ensemble model (CODEm) and Spatiotemporal Gaussian Process Regression (ST-GPR) were used to model our data and estimate each quantity of interest. Mortality to incidence ratios (MIR) were used to generate incidence and survival from mortality rate. Prevalence and survival were used to generate years lived with disability (YLDs). Age-specific mortality and life expectancy at the same age were used to estimate years of life lost (YLLs). The sum of YLLs and YLDs generates DALYs. Results The total national incidence of leukemia increased from 6092 (UI 95%: 3803-8507) in 1990 to 6767 (4646-7890) new cases in 2019. However, leukemia age-standardized incidence ratio(ASIR) decreased from 11.6 (8-14.8) to 8.9 (6.2-10.3) new cases per 100,000 in this exact period. At the national level, deaths from leukemia increased 1.5-fold between 1990 and 2019, from 3287 (2284-4201) to 4424 (3137-5030), whereas the age-standardized death rate(ASDR) decreased from 8.3 (6.1-9.8) in 1990 to 6 (4.3-6.8) per 100,000 in 2019. In the study period, total leukemia DALYs decreased 12.2% and reached 162850 (110681- 188806), in 2019. The age-standardized DALYs decreased 36.7% from 324.3 (224.8- 413.4) in 1990 to 205.3 (140.3-237.8) in 2019. ASDR, DALYs, YLLs, and YLDs rate to high BMI was increasing while smoking and occupational exposure to benzene and formaldehyde were decreasing in the study period. Conclusion This study provided a better understanding of leukemia burden and to reduce controversies of leukemia across Iran. The leukemia status alteration of the country, is trackable. © 2023 Poopak et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Experts (# of related papers)
Other Related Docs
12. Principles of Pharmacogenomics and Pharmacogenetics, Precision Medicine in Clinical Practice (2022)
32. Direct and Indirect Medical Costs of Bladder Cancer in Iran, Cost Effectiveness and Resource Allocation (2023)
33. The Epidemiology of Brain and Spinal Cord Tumors, Advances in Experimental Medicine and Biology (2023)